Industry Awaits US Appeal Ruling On Sandoz’ Enbrel Biosimilar
Sandoz’ Erelzi Version Held Up By IP Barriers
Executive Summary
Sandoz’ attempts to imminently break into the $5bn Enbrel market in the US rest largely on a Court of Appeals ruling that would have to reverse an unfavorable district court decision issued in August last year. A decision may be forthcoming in the next few weeks.
You may also be interested in...
What's Next? Five Things To Look Out For In July
In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.
Sandoz Will Appeal Against US Enbrel Patent Setback
Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid.
What’s Next? Five Things To Look Out For In July
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.